{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of CI was not reached due to low number of participants with events.","groupId":"OG001","lowerLimit":"2.2","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"3.4","upperLimit":"30.3","value":"30.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"DOR is defined as the time in months from the date of first documentation of a CR or PR to the date of first documentation of tumor progression or PD per IRF assessment according to IWG criteria or to death due to any cause, whichever comes first. CR is defined as the disappearance of all evidence of disease and PD is defined as any new lesion or increase by \\>50% of previously involved sites from nadir.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity.","id":"OG000","title":"Brentuximab Vedotin 1.4 mg/kg: Phase 1"},{"description":"Participants with r/r HL received brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle until there was evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.","id":"OG001","title":"Brentuximab Vedotin 1.8 mg/kg: Phase 1 and 2 r/r HL Only"},{"description":"Participants with r/r systemic anaplastic large-cell lymphoma (sALCL) received brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle until there was evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.","id":"OG002","title":"Brentuximab Vedotin 1.8 mg/kg: Phase 1 and 2 r/r sALCL Only"}],"paramType":"MEDIAN","populationDescription":"Participants with response from the Safety Population, all enrolled participants who received at least one dose of brentuximab vedotin, with data available for analysis. Duration of response was censored at last observation documenting absence of PD for participants who did not have tumor progression.","reportingStatus":"POSTED","timeFrame":"Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT and then every 12 weeks for 12 months after EOT, until disease progression, or death or end of study (Up to 72 months)","title":"Duration of Response (DOR) (Phase 1 and 2)","type":"SECONDARY","unitOfMeasure":"months"}